Even though endocrine therapy is preferable over PFS and quality of life (in the absence of a visceral crisis), and approximately 40% of BC in our study were HR-positive/HER2-negative, only 6.9% of patients received endocrine therapy. Here, ERBB2 is linked to breast cancer.